STAAR Surgical (STAA) Expected to Post Earnings of $0.03 Per Share

Equities research analysts expect that STAAR Surgical (NASDAQ:STAA) will report $0.03 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for STAAR Surgical’s earnings. STAAR Surgical reported earnings of $0.02 per share in the same quarter last year, which indicates a positive year over year growth rate of 50%. The business is expected to report its next earnings report on Thursday, March 1st.

According to Zacks, analysts expect that STAAR Surgical will report full year earnings of $0.02 per share for the current financial year. For the next year, analysts forecast that the business will report earnings of $0.19 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for STAAR Surgical.

Several research analysts have recently weighed in on the stock. Benchmark restated a “buy” rating and set a $21.00 price objective on shares of STAAR Surgical in a research note on Monday, November 20th. BidaskClub downgraded shares of STAAR Surgical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Finally, Canaccord Genuity lifted their target price on shares of STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $17.67.

STAAR Surgical (NASDAQ:STAA) opened at $15.20 on Wednesday. The firm has a market cap of $631.87, a PE ratio of -380.00 and a beta of 1.25. STAAR Surgical has a 52 week low of $8.95 and a 52 week high of $17.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.72 and a current ratio of 2.24.

In related news, VP Keith Holliday sold 6,000 shares of STAAR Surgical stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $16.65, for a total transaction of $99,900.00. Following the completion of the sale, the vice president now owns 45,969 shares of the company’s stock, valued at approximately $765,383.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Virtu KCG Holdings LLC bought a new stake in shares of STAAR Surgical during the 2nd quarter worth about $118,000. Prudential Financial Inc. bought a new stake in STAAR Surgical in the 3rd quarter valued at about $138,000. Citadel Advisors LLC bought a new stake in STAAR Surgical in the 3rd quarter valued at about $172,000. Simplex Trading LLC boosted its holdings in STAAR Surgical by 44.3% in the 3rd quarter. Simplex Trading LLC now owns 18,435 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 5,656 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in STAAR Surgical by 68.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 19,073 shares of the medical instruments supplier’s stock valued at $206,000 after purchasing an additional 7,729 shares during the period. 77.97% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/staar-surgical-staa-expected-to-post-earnings-of-0-03-per-share.html.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply